mySELF
Autoimmune disease target discovery - Immunogenic and tolerogenic self-antigen prediction
mySELF applies our immunogenicity prediction to autoimmune disease. It ranks self-peptides by predicted CD8+ and CD4+ immunogenicity to identify likely disease drivers and performs region-level analysis across protein sequences to support tolerance-oriented, antigen-specific therapeutic design.
What mySELF delivers
Large-scale patient-cohort analyses have an average turnaround time of two to three months:
- Epitope prioritization: robust CD8 epitope prioritization for pathogenic mechanism and target discovery
- CD4 region assessment: region-based CD4 analysis aligned with tolerance-oriented concepts
- Final epitope selection: rational narrowing of large autoimmune candidate spaces
- Data integration: integration with HLA, expression, immunopeptidomics, and TCR datasets
What is mySELF?
mySELF applies myNEO's immunogenicity prediction to autoimmune disease. It ranks self-peptides by predicted CD8+ and CD4+ immunogenicity to identify likely disease drivers and performs region-level analysis across protein sequences to support tolerance-oriented, antigen-specific therapeutic design.
What is the typical turnaround for mySELF?
Large-scale patient-cohort analyses with mySELF have an average turnaround time of two to three months.